The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and intends to acquire…
